Amneal Pharmaceuticals (NYSE:AMRX) Posts Earnings Results, Misses Expectations By $0.09 EPS

Amneal Pharmaceuticals (NYSE:AMRX) released its earnings results on Wednesday. The company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.09), Briefing.com reports. The business had revenue of $378.30 million for the quarter, compared to the consensus estimate of $403.90 million. Amneal Pharmaceuticals had a positive return on equity of 28.20% and a negative net margin of 3.65%. The company’s revenue for the quarter was down 20.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.28 earnings per share.

Amneal Pharmaceuticals stock traded down $0.11 during midday trading on Thursday, reaching $2.65. The stock had a trading volume of 1,939,659 shares, compared to its average volume of 1,461,366. Amneal Pharmaceuticals has a 12 month low of $2.27 and a 12 month high of $20.96. The firm’s 50-day moving average price is $3.11 and its 200 day moving average price is $5.44. The firm has a market capitalization of $1.02 billion, a PE ratio of 2.79, a P/E/G ratio of 0.98 and a beta of 1.48. The company has a quick ratio of 1.41, a current ratio of 2.17 and a debt-to-equity ratio of 3.66.

AMRX has been the topic of a number of recent analyst reports. Royal Bank of Canada cut Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $11.00 to $6.00 in a research note on Thursday, July 11th. BMO Capital Markets lowered their target price on Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating on the stock in a research note on Tuesday, August 6th. Zacks Investment Research cut Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 23rd. Guggenheim initiated coverage on Amneal Pharmaceuticals in a research note on Thursday, September 12th. They set a “sell” rating and a $2.50 target price on the stock. Finally, Leerink Swann cut Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $9.00.

In related news, Director Ted C. Nark purchased 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were purchased at an average cost of $2.39 per share, for a total transaction of $119,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Pradeep Bhadauria purchased 30,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $2.41 per share, for a total transaction of $72,300.00. The disclosure for this purchase can be found here. Insiders own 25.92% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Story: Cost of Equity For A Business, Investors

Earnings History for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.